<SEC-DOCUMENT>0001178913-24-001887.txt : 20240530
<SEC-HEADER>0001178913-24-001887.hdr.sgml : 20240530
<ACCEPTANCE-DATETIME>20240530070012
ACCESSION NUMBER:		0001178913-24-001887
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240530
FILED AS OF DATE:		20240530
DATE AS OF CHANGE:		20240530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		241000669

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2431543.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Washington, D.C. 20549<br>
        </font><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Form 6-K</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">For the month of May 2024</div>
    <div style="text-align: center; line-height: 1.25;">Commission File Number 000-30902</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">COMPUGEN LTD.</div>
    <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">26 Harokmim Street</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Holon 5885849, Israel</div>
    <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">Form 20-F &#9746;&#8195;&#8195;Form 40-F &#9744;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compugen Ltd.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">On May 30, 2024, Compugen Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;)
      issued a press release, a copy of which is furnished as Exhibit 99.1 (the &#8220;<font style="font-weight: bold;">Press Release</font>&#8221;) to this Report on Form 6-K and incorporated by reference
      herein.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">With the exception of the third paragraph in the Press Release, the information incorporated by reference in this Report on Form 6-K is
        hereby incorporated by reference into the Company&#8217;s Registration Statement on Form F-3, File No. 333-270985.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zce47b7fe760342d38f6171b8a68e031a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 10.58%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;"><u>Exhibit</u></div>
          </td>
          <td style="width: 89.42%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.58%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;"><u>Number</u></div>
          </td>
          <td style="width: 89.42%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;"><u>Description of Exhibit</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.58%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 89.42%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.58%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">99.1</a></div>
          </td>
          <td style="width: 89.42%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">Compugen to Receive
                Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig</a></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Signatures</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
      behalf by the undersigned thereunto duly authorized.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="za90e516cf419404787817273e9231d28" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: bottom;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
          </td>
          <td style="width: 11%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: bottom;" colspan="4">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Date: May 30, 2024</div>
          </td>
          <td style="width: 4%; vertical-align: bottom;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">/s/ Eran Ben Dor</div>
          </td>
          <td style="width: 11%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Eran Ben Dor</div>
          </td>
          <td style="width: 11%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: bottom;">
            <div style="line-height: 1.25;">General Counsel</div>
          </td>
          <td style="width: 11%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: right; line-height: 1.25;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><img width="122" height="35" src="image0.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Compugen to Receive Milestone Payment Triggered by Dosing of First Patient </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">in the Second Phase 3 Trial Evaluating Rilvegostomig</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z383ddc4282944f1582f73037f488f70e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo&#8217;s datopotamab deruxtecan in first-line nonsquamous
              non-small cell lung cancer</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z560a8acaf490487f8abafa09a6c68d90" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Broadening the assessment of rilvegostomig reinforces Compugen&#8217;s partnering strategy to expand opportunities for its pipeline</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z80255140e35b4809b2aef035cf870a17" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div>Compugen to receive $5 million milestone payment from AstraZeneca</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">HOLON, ISRAEL,&#160;May 30, 2024&#160;- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in
      computational target discovery, today&#160;announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca&#8217;s PD-1/TIGIT
      bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen&#8217;s clinical-stage anti-TIGIT antibody, COM902. Both rilvegostomig and COM902 are designed to have reduced Fc effector function.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">The trial, called TROPION-Lung10, is evaluating the efficacy and safety of rilvegostomig as monotherapy and in combination with datopotamab
      deruxtecan (Dato-DXd), AstraZeneca and Daiichi Sankyo&#8217;s (TSE: 4568) TROP2-directed antibody drug conjugate versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high
      PD-L1 expression (TC &#8805; 50%) and without actionable genomic alterations. The trial is sponsored by AstraZeneca in collaboration with Daiichi Sankyo and is expected to enrol approximately 675 patients in more than 14 countries. Further details about
      TROPION-Lung10 are available on ClinicalTrials.gov, identifier: <u>NCT06357533</u>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">&#8220;We are very excited to see the advancement of rilvegostomig into its second Phase 3 trial by AstraZeneca in collaboration with Daiichi
      Sankyo, two global leaders in oncology,&#8221; said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. &#8220;TROPION-Lung10 follows the start of the ARTEMIDE-Biliary01 Phase 3 trial evaluating rilvegostomig in biliary tract cancer, for
      which we received a $10 million milestone payment. Now, after dosing the first patient in this lung cancer trial, we are eligible to receive a $5 million milestone payment from AstraZeneca. Broadening the assessment of rilvegostomig reinforces our
      partnering strategy to expand opportunities for our pipeline and brings us closer to realizing potential future milestone payments and royalties.&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">The ARTEMIDE-Biliary01 Phase 3 trial is evaluating the efficacy and tolerability of rilvegostomig compared to placebo in combination with
      investigator&#8217;s choice of chemotherapy in patients with biliary tract cancer after surgical resection with curative intent. Further details about the ARTEMIDE-Biliary01 trial are available on ClinicalTrials.gov, identifier: <u>NCT06109779</u>.</div>
    <div style="line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">About the Compugen-AstraZeneca license agreement</div>
    <div style="line-height: 1.25;">In 2018, Compugen and AstraZeneca entered into an agreement by which Compugen provided an exclusive license to AstraZeneca to use
      Compugen&#8217;s monospecific antibodies that bind to TIGIT, including COM902, for the development of bispecific and multispecific antibody products, excluding such bispecific and multispecific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT.
      AstraZeneca is responsible for all research, development, and commercial activities. AstraZeneca has the right to create multiple products under this license. Compugen has received $35.5 million in upfront and milestone payments to date and is
      eligible to receive an additional $5 million milestone payment as described in this press release. Compugen is eligible to receive up to an aggregate milestone amount of $200 million in development and regulatory milestones for the first and second
      indications for the first product and commercial milestones for the first product, as well as tiered royalties on future product sales. If additional bi- or multi-specific products are developed based on Compugen&#8217;s monospecific antibodies that bind
      to TIGIT, additional milestones and royalties would be due to Compugen.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Rilvegostomig (previously AZD2936) is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen&#8217;s clinical stage
      anti-TIGIT antibody, COM902. Rilvegostomig is in Phase 3 development by AstraZeneca through this license agreement. Both rilvegostomig and COM902 are designed to have reduced Fc effector function to avoid depletion of CD8+ T cells.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">About&#160;Compugen</div>
    <div style="line-height: 1.25;">Compugen&#160;is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational
      discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies.&#160;Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902,&#160;a
      potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen&#8217;s clinical stage anti-TIGIT antibody, COM902, is in Phase 3
      development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies.&#160;In addition, the Company&#8217;s therapeutic pipeline of early-stage&#160;immuno-oncology programs consists of programs aiming to address
      various mechanisms of immune resistance, of which the most advanced program, COM503, in IND enabling studies is licensed to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding
      protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen&#160;is headquartered in Israel, with offices in San Francisco, CA. Compugen&#8217;s shares are listed on Nasdaq and the Tel Aviv&#160;Stock Exchange
      under the ticker symbol CGEN.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Forward-Looking Statement</div>
    <div style="line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Securities Act of 1933 and the Securities Exchange Act
      of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can
      be identified using terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;confident,&#8221; and &#8220;intends,&#8221; and similar expressions that are intended to identify
      forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements relating to our expectation to receive the milestone payment from
      AstraZeneca and statements regarding the progress of the rilvegostomig clinical program. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to
      be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen&#8217;s business model is substantially dependent on entering into collaboration agreements
      with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen&#8217;s approach to the discovery of therapeutic products is based on its proprietary computational target
      discovery infrastructure, which is unproven clinically; Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value; and the general market, political and economic
      conditions in the countries in which Compugen operates, including Israel; and the effect of the evolving nature of the recent war in Gaza between Israel and Hamas. These risks and other risks are more fully discussed in the &#8220;Risk Factors&#8221; section of
      Compugen&#8217;s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking
      statements represent Compugen&#8217;s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless
      required by law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Company contact:</div>
    <div style="line-height: 1.25;">Yvonne Naughton, Ph.D.</div>
    <div style="line-height: 1.25;">Head of Investor Relations and Corporate Communications</div>
    <div style="line-height: 1.25;">Email:&#160;ir@cgen.com</div>
    <div style="line-height: 1.25;">Tel: +1&#160;(628)&#160;241-0071&#160;&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W +\# 2(  A$! Q$!_\0
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M+&3Y:DN?%2@Z?L874$N2<ZR4(W4;.*J<T>:_XGGF9YWFV*P> PT_8XG&YC#
MPYJ:Y,'":DZLVKMITX4;SDKRO&;I\LK-:GP-_83^)WQZA/[2'[:GC?Q)\/\
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&HKB/0/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
